Krensavage Asset Management, LLC Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001609251

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 20 positions · Total reported value $265.38M · Top-10 concentration 88.1% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 33.3% · 3 new · 3 cut · 1 exited

Active Share (vs S&P 500): 99.7% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -6.0% · vs SPY -8.2% · Prev Value $263.22M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -0.5% · vs SPY -2.7% · Latest Value $265.38M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Krensavage Asset Management, LLC disclosed 20 equity positions with a combined reported value of $265.38M. The filing implies a focused portfolio: its ten largest positions account for 88.1% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were JAZZ ($38.85M), ENTA ($37.78M), UTHR ($35.92M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, Krensavage Asset Management, LLC opened 3 new positions, trimmed 3 and fully exited 1, a turnover rate of 33.3% of positions. The portfolio's overlap with the prior quarter was 81% of names.

The largest new positions opened in Q3 2026 were ANIP ($944.00K), ACAD ($806.00K), ZTS ($698.00K).

Of the 1 positions fully exited versus the prior quarter, the largest were REGN ($3.74M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • ANIP ANI PHARMACEUTICALS INC · $944.00K
  • ACAD ACADIA PHARMACEUTICALS INC · $806.00K
  • ZTS ZOETIS INC · $698.00K

Fully Exited (vs previous quarter)

  • REGN REGENERON PHARMACEUTICALS · prev qtr: $3.74M

Insider Transactions (Form 4)

Latest Krensavage Asset Management, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Krensavage Asset Management, LLC, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 20 positions worth $265.38M in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-78631 (status: Approved), registered 2013-10-04
  • Regulatory AUM (Form ADV): $300.23M as of 2026-03-25
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 1 private funds, of which 1 hedge funds

Portfolio Structure

  • 20 positions · $265.38M reported value (Q3 2026)
  • Top 10 holdings = 88.1% of reported value
  • Largest position: JAZZ (JAZZ PHARMACEUTICALS PLC) at 14.6%
  • Average position size: $13.27M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 3 new, 4 added, 3 reduced, 1 exited
  • 10 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund maintains a concentrated, healthcare-focused portfolio with modest adjustments, suggesting a neutral-to-bullish view on biotech/healthcare but with selective profit-taking (reduces in UTHR, EXEL) and targeted bets on high-growth names (adds in RARE, SUPN). 2. Key moves: - Added: RARE (+191.9% shares, +1.50% wt), SUPN (+24.9% shares, +0.73% wt), SNY (+3.1% shares, -0.06% wt). - Reduced: UTHR (-4.3% shares, -0.73% wt), EXEL (-19.2% shares, -1.07% wt). 3. Portfolio structure: Active, concentrated (20 positions, 84% top-10 weight), heavily biased toward Health Care (100%), with moderate risk appetite (mix of large-caps like ABT/SNY and high-growth biotechs like RARE/EXEL). 4. Per-holding one-liner: - JAZZ: Biopharma (neurology/oncology) - ENTA: Hepatitis B drug developer - UTHR: Pulmonary hypertension therapies - BMRN: Rare disease treatments (e.g., MPS I) - ABT: Diversified healthcare (devices/pharma) - EXEL: Cancer drug developer (Cabometyx) - RARE: Rare disease therapies (e.g., MPS IIIB) - SUPN: CNS/neurology drugs (e.g., Oxtellar) - SNY: Large-cap pharma (vaccines/diabetes) - EMBC: Medical devices (vascular access) 5. Style summary: Healthcare-focused active manager with selective growth tilt, trimming overexposed names and doubling down on high-potential biotech catalysts.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-18 03:44

Sector Allocation

Health Care 100.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 167.82K $38.85M 14.64%
14.64%
Hold
2 2.87M $37.78M 14.23%
14.23%
Hold
3 66.28K $35.92M 13.53%
13.53%
Reduce
4 524.79K $31.49M 11.87%
11.87%
Hold
5 200.00K $19.77M 7.45%
7.45%
Hold
6 299.39K $17.49M 6.59%
6.59%
Reduce
7 1.14M $17.15M 6.46%
6.46%
Add
8 350.68K $15.09M 5.69%
5.69%
Add
9 333.95K $13.77M 5.19%
5.19%
Add
10 1.14M $6.43M 2.42%
2.42%
Hold
11 1.82M $6.21M 2.34%
2.34%
Add
12 59.52K $5.85M 2.21%
2.21%
Hold
13 1.18M $5.80M 2.18%
2.18%
Hold
14 96.73K $4.66M 1.76%
1.76%
Hold
15 20.00K $4.52M 1.70%
1.70%
Hold
16 120.94K $1.71M 0.65%
0.65%
Hold
17 13.00K $944.00K 0.36%
0.36%
New
18 40.00K $806.00K 0.30%
0.30%
New
19 10.00K $698.00K 0.26%
0.26%
New
20 57.98K $464.00K 0.17%
0.17%
Reduce

FAQ

What did Krensavage Asset Management, LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, Krensavage Asset Management, LLC reported 20 equity positions worth $265.38M in aggregate; its largest disclosed positions were JAZZ ($38.85M), ENTA ($37.78M), UTHR ($35.92M).

How large is Krensavage Asset Management, LLC's portfolio?

Krensavage Asset Management, LLC reported $265.38M of long equity holdings across 20 positions as of 2026-Q3. Top-10 holdings account for 88.1% of reported value.

What is Krensavage Asset Management, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/krensavage-asset-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →